Clinical Trials Directory

Trials / Completed

CompletedNCT02479165

Pain Management After Cardiac Surgery - Opioids or NSAID

Pain Management After Cardiac Surgery - Opioids or NSAID? A Randomized Prospective Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
182 (actual)
Sponsor
Aalborg University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this randomized controlled study is to shed light on the analgesic properties and side-effect profile of an opiod-based regimen as opposed to an Ibuprofene based regimen.

Detailed description

Background: Postoperative pain following median sternotomy can represent a major postoperative problem as it can lead to reduced mobilization and shallow, restricted breathing and insufficient cough, which can lead to pulmonary complications. However, pain management with opioids has frequent side-effects such as confusion, respiratory depression, sedation, nausea and obstipation/ paralytic ilieus. Non-steroid anti-inflammatory drugs (NSAIDs) can been used as opiod-sparing analgesics following cardiac surgery. However, this remains controversial, as NSAIDs has been linked to an increased risk of myocardial infarction, especially in patients with ischaemic heart disease, renal failure, gastrointestinal bleeding, and possibly impaired sternal healing. The investigators wanted to investigate the analgesic properties of a opiod-based regimen with that of an ibuprofene-based, through randomization of patients to one of the two arms. Intervention: The participants were given analgesics in accordance to their randomization group upon return from the postoperative ICU stay. The opioid regimen relied on a basic dose of slow-release oxycodone ("Oxycontin", Norpharma, Vedbaek, Denmark, 10mg two times daily) and paracetamol ("Panodil", GlaxoSmithKline, Copenhagen, Denmark, 1g four times daily). For "break-through pain" extra oxycodone was administered as injections or capsules (5mg pr. dose). Furthermore laxatives were co-administered to prevent obstipation. In the ibuprofene regimen slow-release ibuprofen ("Brufen Retard", Abbott, Copenhagen, Denmark, 800mg two times daily) replaced oxycodone as the basic analgesic. In the ibuprofene regimen lansoprazol ("Lansoprazole", Actavis, Gentofte, Denmark, 30mg once daily) was co-administered to prevent development of gastric ulcers. These regimens were initiated the first postoperative day, when the patient was transferred from the ICU to the ward, and continued until the seventh postoperative day. Some patient Outcome: Please refer to the "outcome" chapter Statistics: Data are presented as number of patients, medians, and ranges. Patients are compared according to the ibuprofen or the oxycodone group, and statistics were done using "intention-to-treat"-design. Fischer's exact test, Mann-Whitney, and 95% confidence intervals were used as appropriate. Significance was defined as P-values below 0.05.

Conditions

Interventions

TypeNameDescription
DRUGIbuprofeneThe Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
DRUGOxycodoneThe opioid group is given an oxycodone based analgesic regimen.

Timeline

Start date
2009-05-01
Primary completion
2010-09-01
Completion
2013-09-01
First posted
2015-06-24
Last updated
2015-06-24

Source: ClinicalTrials.gov record NCT02479165. Inclusion in this directory is not an endorsement.